Skip to content

In the BioHarmony Drug Report Database

Tasimelteon

Hetlioz (tasimelteon) is a small molecule pharmaceutical. Tasimelteon was first approved as Hetlioz on 2014-01-31. It is used to treat circadian rhythm sleep disorders in the USA. It has been approved in Europe to treat circadian rhythm sleep disorders. The pharmaceutical is active against melatonin receptor type 1A and melatonin receptor type 1B. Hetlioz's patents are valid until 2035-08-29 (FDA).
Trade Name Hetlioz
Common Name Tasimelteon
Indication circadian rhythm sleep disorders
Drug Class Selective melatonin receptor agonist
Tasimelteon
Get full access now